Author Index of Volume 4, 1981/82

Alexander E. L. 253

Bloom B. R. 397

Carson D. A. 161
Chattopadhyay C. 125

De Fabo E. C. 293
Dobloug J. H. 125

Ferrell P. B. 181
Fong S. 161
Førre Ø. 125

Geha R. S. 275
Gigli I. 209, 305
Gilliam J. N. 1

Hall R. P. 33, 221
Hannestad K. 133
Haran-Ghera N. 373
Hashimoto K. 17
Hoffman W. L. 103
Husebekk A. 133

Jaffe I. A. 193

Katz E. 373
Katz S. I. 33
Kazmierowski J. A. 45
Klein G. 309
Kripke M. L. 293
Kunkel H. G. 85

Lawley T. J. 33, 221
Lawrance S. K. 161
Lazarus G. S. 17
Leung D. Y. M. 275
Lim H. 209
Lonai P. 373

Mihm M. C. 65
Natvig J. B. 125
Noonan F. P. 293

Pasquali J.-L. 161
Provost T. T. 253
Quie P. G. 241

Rager-Zisman B. 397
Rekvig O. P. 133

Singer K. H. 17
Slaughter L. 161
Slovin S. F. 161
Smiley J. D. 103
Sontheimer R. D. 1
Soter N. A. 55, 73
Stutman O. 333

Tan E. M. 181
Tsoukas C. T. 161

Vandeputte M. 317
Vaughan J. H. 161

Winchester R. J. 89
Wintroub B. U. 55, 65
Wuepper K. D. 45

Subject Index

Acantholysis 18
anti-early antigen (EA) 181
anti-idiotype antibodies 163
anti-nuclear antibody (ANA) 135
anti-staphylococcal antibody 244
anti-viral capsid antigen (VCA) 181
atopic dermatitis, immune mechanisms 275
atopic disease 236
autoantibody 17
autoimmune diseases, cutaneous manifestations 229
autoimmune syndromes, induction by penicillamine therapy 193
autoimmunity, penicillamine-related compounds 203
autoimmunization 133

Bullae 18
bullous diseases 234
bullous fluid, mediator content 67
bullous pemphigoid 65, 235
–, inflammation 65
–, eosinophils 65

Cell injury, immunologically mediated epidermal 1
cell-mediated cytotoxicity (CMC) 338
cell-mediated immunity 243
cellular immunity, regulation 128
Chediak-Higashi syndrome 249
chemotactic activity 211
chemotaxis 241
–, cutaneous disorders 246
cholinergic urticaria 73
chromatin 141
chymase 58
classic HLA antigens 93
complement 210
contact hypersensitivity, suppression of 293
contact sensitivity, inhibition of induction 305

Dermal-epidermal junction 65
dermatitis herpetiformis 33, 234

Eosinophil chemotactic factors 57
eosinophil granules 67
epidermal basement membrane zone 66
Epstein-Barr virus (EBV) 181, 168
EBV determined nuclear antigen (EBNA) 185
erythema multiforme 45, 236

Glucocorticosteroids 305
gluten-sensitive enteropathy (GSE) 38
Goodpasture's syndrome 196

H-2 gene products 391
H-2 linked resistance
–, immunologic nature 381
–, preleukemia arrest 385
H-2 linked Ir genes 391
H-2 linked leukemia resistance genes 378
H-2 linked resistance loci 375
–, leukemogenesis and lymphoma transplantation 379
high molecular weight neutrophil chemotactic factor (HMW-NCF) 57
histamine 56
histocompatibility markers, rheumatoid arthritis 91
histones 141
HLA antigens 93
HLA-DR4 89
host defence 241
hyperimmunoglobulin E syndrome 242, 243

Ia alloantigens 93
idiotypes 145, 162
IgA 33
IgE 243
IgG 18
IgG-3 subclass 115
immobile cilia syndrome 248
immune complex assays 225
immune complexes, circulating 221
–, disease findings 229
immune mechanisms, atopic dermatitis 275
immunoglobulin 109
inflammation 248
–, chronic cutaneous 73
inflammatory response 55
intercellular cement substance (ICS) 18
Interferon 400

Keratinocytes 1

La (SSB) autoantibody system 253
Langerhans cells 1
Langerhan's cells, decreased density 305
LE factors 133
lichenoid skin diseases 9
lupus, penicillamine-induced 198
lymphocyte chemoattractant activity 69
lymphocyte response 247

Major histocompatibility complex 373
–, rheumatoid arthritis 89
mammary tumor virus (MuMTV) 333

mast cell activation, in vivo model 73
mast cell 66
–, chemical mediators 55
–, chemotactic factors 57
–, eosinophil chemotactic factors 66
–, release reaction 59
–, skin 73
melanocytes 1
membranous nephropathy 196
mixed connective tissue disease 231
myasthenia gravis 193

Natural-cell-mediated cytotoxicity (NCMC) 337
natural killer (NK) cells 397
neoplastic diseases 409
nucleosomes 141

Oncogenic viruses 312

Pemphigus 17
–, and pemphigoid 195
pemphigus vulgaris 235
penicillamine, lupus 198
phagocytic cell dysfunction 241
phototoxicity 209
physical urticaria/angioedema 73
–, cold-induced 73
pokeweed mitogen 168
polymyositis 199
polyoma tumors
–, immunopathology 317–332
–, immune reactions in vivo 317–332
–, immune reactions in vitro 317–332
–, immunosuppression 317–332
–, tumor antigens 317–332
porphyria 209
proteinase 23

Resistance to viral diseases 397
rheumatoid arthritis 133, 162, 181
–, ethnic relationships 94
–, family studies 89
–, histocompatibility markers 91
–, immunoregulation 125
–, major histocompatibility complex 89
–, pathogenic considerations 116
–, relative risk 90
–, seropositive and seronegative 89
–, susceptibility 89
RA-associated nuclear antigen (RANA) 181
rheumatoid factors 111
–, physiology and pathology 161
–, cross reaction 133
rheumatoid synovial tissue 103
Ro (SSA) autoantibody system 253

Scleroderma 231
Sjögren's syndrome 199, 253
slow-reacting substance of anaphylaxis (SRS-A) 57
suppressor T cells 352
systemic lupus erythematosus 133, 253

T cells 345
thymectomy 356
thyroiditis 199
tumor immunology, surveillance 309
tumor rejection 310
tumor specific transplantation antigen (TSTA) 311

Vasculitis 231
viral leukemia, role of humoral immunity 384

Springer Seminars in Immunopathology

Peter A. Miescher, Geneva
Hans J. Mueller-Eberhard, La Jolla

Volume 4 1981/82

Advisory Board

B. Benacerraf, Boston, MA
M. D. Cooper, Birmingham, AL
F. J. Dixon, La Jolla, CA
K. Eichmann, Heidelberg
G. Klein, Stockholm
R. Krause, Bethesda, MD
H. G. Kunkel, New York, NY
P. Lachmann, Cambridge
P. H. Lambert, Geneva
J. B. Natvig, Oslo

Springer International

Springer Seminars in Immunopathology

With the acceptance of the manuscript for publication the exclusive copyright for all languages and countries, including the right for photomechanical and any other reproduction, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Authors of this journal can benefit from library and photocopy fees collected by VG WORT if certain conditions are met. If an author lives in the Federal Republic of Germany or in West Berlin it is recommended that he contacts Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestrasse 49, D-8000 München 2, for detailed information.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed in Germany by Oscar Brandstetter Druckerei GmbH & Co. KG, Wiesbaden

© Springer-Verlag GmbH & Co. KG, Berlin Heidelberg New York 1981/82

Contents of Volume 4, 1981/82

Number 1 issued in June 1981

Immunodermatology I

Guest Editor: I. N. Gigli

1 **R. D. Sontheimer, J. N. Gilliam:** Immunologically Mediated Epidermal Cell Injury

17 **K. H. Singer, K. Hashimoto, G. S. Lazarus:** Antibody-Induced Proteinase Activation: A Proposed Mechanism for Pemphigus

33 **R. P. Hall, T. J. Lawley, S. I. Katz:** Dermatitis Herpetiformis

45 **J. A. Kazmierowski, K. D. Wuepper:** Erythema Multiforme: Clinical Spectrum and Immunopathogenesis

55 **B. U. Wintroub, N. A. Soter:** Biology of the Mast Cell and its Role in Cutaneous Inflammation

65 **B. U. Wintroub, M. C. Mihm:** Mast Cell-Dependent Effector Pathways and Cutaneous Bullous Disorders

73 **N. A. Soter:** Physical Urticaria/Angioedema as an Experimental Model of Acute and Chronic Inflammation in Human Skin

83 *Erratum*

Number 2 issued in September 1981

Rheumatoid Arthritis

Guest Editor: H. G. Kunkel

85 **H. G. Kunkel:** Introduction

89 **R. J. Winchester:** Genetic Aspects of Rheumatoid Arthritis

103 **J. D. Smiley, W. L. Hoffman:** Protein Synthesis in Rheumatoid Synovial Tissue

125 **J. H. Dobloug, Ø. Førre, C. Chattopadhyay, J. B. Natvig:** Evidence for Altered Immunoregulation in Rheumatoid Arthritis

133 **K. Hannestad, O. P. Rekvig, A. Husebekk:** Cross-Reacting Rheumatoid Factors and Lupus Erythematosus (LE)-Factors

161 **D. A. Carson, J.-L. Pasquali, C. T. Tsoukas, S. Fong, S. F. Slovin, S. K. Lawrance, L. Slaughter, J. H. Vaughan:** Physiology and Pathology of Rheumatoid Factors

181 **P. B. Ferrell, E. M. Tan:** Epstein-Barr (EB) Virus Antibodies in Rheumatoid Arthritis

193 **I. A. Jaffe:** Induction of Auto-Immune Syndromes by Penicillamine Therapy in Rheumatoid Arthritis and Other Diseases

Number 3 issued in December 1981

Immunodermatology II

Guest Editor: I. N. Gigli

209 **H. Lim, I. Gigli:** The Role of Complement in Phototoxic Reactions

221 **T. J. Lawley, R. P. Hall:** Circulating Immune Complexes in Dermatologic Disease

241 **P. G. Quie:** Infections in Patients with Abnormal Granulocyte Chemotaxis

253 **E. L. Alexander, T. T. Provost:** Ro(SSA) and La(SSB) Antibodies

275 **D. Y. M. Leung, R. S. Geha:** Immune Mechanisms in Atopic Dermatitis

293 **F. P. Noonan, E. C. De Fabo, M. L. Kripke:** Suppression of Contact Hypersensitivity by Ultraviolet Radiation: An Experimental Model

305 **I. Gigli:** Conclusions

Number 4 issued in June 1982

Immunopathology of Virally Induced Tumors I

Guest Editor: G. Klein

309 **G. Klein:** Introduction

317 **M. Vandeputte:** Immunopathology of Polyoma-Induced Tumors

333 **O. Stutman:** Natural and Induced Immunity to Mouse Mammary Tumors and the Mammary Tumor Virus (MuMTV)

373 **P. Lonai, E. Katz, N. Haran-Ghera:** Role of the Major Histocompatibility Complex in Resistance to Viral Leukemia; Its Effect on the Preleukemic Stage of Leukemogenesis

397 **B. Rager-Zisman, B. R. Bloom:** Natural Killer Cells in Resistance to Virus-Infected Cells

Indexed in Current Contents